ABECMA (idecabtagene vicleucel)
ABECMA is the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapies including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
Recommend0 recommendationsPublished in US National Health Agency Sources